Aptevo Therapeutics Stock News

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday The Dow traded up 0.84% to 33,757.34 while the NASDAQ rose 0.37% to 11,045.45. The S&P 500 also r

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday Following the market opening Monday, the Dow traded up 0.35% to 33,592.23 while the NASDAQ rose 0.01% to 11

Retail investors are skittish about this market, and understandably. Our call of the day says that may only help lure back influential investors in the new year.

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares rose 104% to $7.00 in pre-market trading. Aptevo Therapeutics said 100% clinical benefit rate was achieved in Phase 1b trial evaluating Apvo436

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) delivered earnings and revenue surprises of 22.99% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results.  Aptevo said royalty revenue totaled $12.3 million in 2021, up from roya

Aptevo Therapeutics Inc (NASDAQ: APVO ) earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management LLC . Additionally, the Company is optimistic about the possibility of earning additional milestones totaling $22.5 million over the next two years. The Company Full story available on Benzinga.com

Gainers US Ecology, Inc. (NASDAQ: ECOL ) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (NASDAQ: DCFC ) gained 65.4% to $15.78. Tritium DCFC shares surged nearly 40% Tuesday after the Australian EV charging company announced its new manufacturing facility will be located in the United States. Tritium CEO Jane Hunter appeared at the White House to make the announcement yesterday. Infobird Co., Ltd (NASDAQ: IFBD ) gained 32.6% to $1.2393. Infobird recently signed a contract with subsidiary of Nippi Japan for digital marketing solutions. Doximity, Inc. (NYSE: DOCS ) shares gained 25.1% to $62.30 after the company reported better-than-expected Q3 results and issued FY22 sales guidance above estimates. Aptevo Therapeutics Inc. (NASDAQ: APVO ) jumped 20.5% to $7.29 after the company announced it has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE. Absolute Software Corporation (NASDAQ: ABST ) gained 17.9% to $9.47 after the company reported better-than-expected Q2 sales results and issued FY22 sales guidance.

Doximity DOCS +20%. Aptevo Therapeutics APVO +17%. Varex Imaging (VREX) -11%. BioCardia (BCDA) -8%.

Aptevo Therapeutics Inc APVO earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Manage

Aptevo Therapeutics (APVO) trades 5.8% higher premarket after the company earned $10M non-dilutive milestone payment related to 2021 sales of RUXIENCE; this is under its royalty

Aptevo Therapeutics (NASDAQ:APVO) was downgraded by investment analysts at UBS Group from a buy rating to a neutral rating in a report issued on Wednesday, The Fly reports. Several other brokerages also recently commented on APVO. Roth Capital lowered their target price on Aptevo Therapeutics from $50.00 to $36.00 and set a buy rating for []

(PR-inside.com) LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies. Nature Communications is an open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of the biological, health, physical, chemical and Earth sciences. The article titled, CD137 (4-1BB) co-stimulation of CD8 T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation, details the ..